Search

Improved efficacy expected with second-generation microinvasive glaucoma surgery (MIGS) devices

Microinvasive surgical approaches to primary open-angle glaucoma (POAG) offer minimally traumatic options for effective intraocular pressure (IOP) reduction in appropriately selected glaucoma patients. Increases in laser trabeculoplasty rates and wider adoption of glaucoma drainage device filtration procedures, together with the...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Tackling diabetic retinopathy globally through the VISION 2020 LINKS Diabetic Retinopathy Network

It is abundantly clear that the burden of diabetes is rapidly increasing, as there are now 415 million adults with diabetes in the world, with a projected rise to 642 million by 2040 [1]. This equates to 1 in 10...

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments

Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...

Retinoblastoma management update (part 1): clinical features, diagnosis and genetics

The first of a two part series, this article will discuss the clinical features, diagnosis and genetic aspects of retinoblastoma. Manoj Parulekar is based at Birmingham Children’s Hospital, one of the two designated national retinoblastoma and paediatric ocular oncology treatment...

Herpes zoster ophthalmicus: a clinician’s perspective

Introduction Herpes zoster, commonly known as shingles, is caused by the reactivation of varicella zoster virus (VZV). The term herpes is derived from a Greek work, herpein, which means ‘creeping’ and the word zoster means a belt or a girdle...

‘Phaco-plus’ procedures at forefront of modern glaucoma management

Glaucoma and cataract increasingly present as a ‘two-in-one’ surgical opportunity. In the UK, new modelling suggests ~1 million adults aged ≥40 may currently have glaucoma, with a projected rise to ~1.6 million by 2060 as the population ages and demographics...

The next wave of AI in ophthalmology: From screening to communication

Artificial intelligence (AI) is reshaping ophthalmology, moving from research laboratories into everyday clinical care [1]. With its strong reliance on imaging and pattern recognition, ophthalmology is uniquely positioned to benefit from AI innovations. These developments range from autonomous disease screening...

Imaging within clinical research trials

Clinical research is essential to the future of healthcare and the wellbeing of patients, no matter what health condition they face. Many patients who choose to participate in clinical research studies in ophthalmology find optimism in discovering novel medicines to...

Addressing childhood blindness in sub-Saharan Africa

In this article, the authors explore paediatric ophthalmology subspecialist fellowship training in African nations south of the Sahara. Until recently, most African ophthalmologists who wished to pursue a subspecialty ophthalmology training fellowship had to go abroad. There is a huge...